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Introduction
A proportion of patients presenting to emergency centres need 
to undergo procedures that can be unpleasant and painful. The 
provision of safe and effective analgesia and procedural sedation is a 
critical aspect of the provision of care in an emergency centre. Given 
the nature of an emergency centre, which is often overwhelming and 
noisy and appears chaotic to patients, the entire clinical experience 
for the patient and ultimately outcome can be improved if appropriate 
and effective procedural sedation is provided. The Emergency 
Medicine Society of South Africa (EMSSA) recognised the lack of 
uniformity on this topic1 and set up an expert panel responsible for 
the drafting of this practice guideline. 
This document is intended as a guide for emergency medicine 
specialists and all medical practitioners involved in the provision of 
emergency procedural sedation in emergency centres in South Africa.
Procedural sedation definition
Procedural sedation refers to a technique of administering sedatives 
or dissociative agents, with or without analgesics, to induce a state that 
allows patients to tolerate unpleasant procedures while maintaining 
cardiorespiratory function and retaining the ability to respond 
purposefully to verbal commands and/or tactile stimulation.2-4 This 
technique is appropriate for both adult and paediatric patients.5
3.  Levels of sedation2,6-8
3.1 Minimal sedation (anxiolysis) is a drug-induced state during 
which patients respond normally to verbal commands. Cognitive 
function and co-ordination may be impaired, but ventilatory and 
cardiovascular systems are unaffected.
3.2 Moderate sedation (previously referred to as conscious 
sedation) is a drug-induced depression of consciousness during which 
patients respond purposefully to verbal or light tactile stimulation. 
The techniques and drugs (in the doses used) are not likely to 
produce loss of protective airway reflexes.
3.3 Deep sedation is a drug-induced depression of consciousness 
during which patients cannot be aroused easily but respond 
purposefully after repeated or painful stimulation. These patients 
may require assistance in maintaining a patent airway and may need 
ventilatory support.
3.4 General anaesthesia refers to a state of drug-induced loss of 
consciousness during which patients are not rousable and may have 
impaired cardiorespiratory function requiring varying degrees of 
support.
3.5 Dissociative sedation is a trance-like cataleptic state characterised 
by profound analgesia and amnesia with retention of protective airway 
reflexes, spontaneous respiration and cardiopulmonary stability. 
Ketamine is the only approved dissociative agent.
Progression from one stage to the next is a continuum, and it is 
often difficult to predict how a patient will respond to a specific 
sedative agent. It is essential that practitioners possess the skills 
necessary to rescue a patient from one level deeper than the desired 
level of sedation.
Recommendations in this guideline are not intended to represent 
the only diagnostic and management options that emergency 
practitioners can apply. The individual physician’s judgement is of 
utmost importance. However, procedural sedation is the recognised 
and validated standard of practice for painful and intimidating 
procedures.
4.  Scope of practice guideline6-8
This practice guideline: 
•    applies to the administration of dissociative agents, sedative agents 
or sedative and analgesic agents together
•   does NOT apply to:
•    administration of agents to facilitate airway management or 
tracheal intubation
•    patients who have already undergone tracheal intubation and 
ventilation
•    refers to the use of moderate sedation and analgesia, and 
deep sedation and analgesia, in order to facilitate diagnostic or 
therapeutic procedures
•    refers to the use of sedative, analgesic and dissociative agents in 
the emergency centre
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Background. The performance of safe and effective procedural 
sedation in the emergency centre has become a core competency in 
emergency medicine internationally. However, in South Africa clear 
guidelines are lacking and this guideline attempts to set out the 
standard for the routine safe use of procedural sedation by clinical 
staff in emergency centres.
Method. The Emergency Medicine Society of South Africa (EMSSA) 
appointed a task group to analyse the international literature and 
guidelines, and a draft document was produced which was revised 
by consensus input from an expert panel.
Results and conclusion. A simple and clear practice guideline has 
been developed for health professionals working in emergency 
centres in South Africa. This guideline will help to improve the 
provision of emergency procedural sedation, which is an important 
component of the care provided in emergency centres. 
S Afr Med J 2010; 100:195-201.
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5.  Objectives of procedural sedation4
The objectives are:
•    to provide adequate analgesia, anxiolysis, sedation and amnesia 
during the performance of painful diagnostic or therapeutic 
procedures
•    to minimise variations in patients’ cardiovascular and respiratory 
physiological parameters
•    to maintain the patient’s protective airway reflexes.
6.  Contraindications to procedural 
sedation4
6.1  Contraindications
Contraindications include:
•    lack of appropriate monitoring equipment, or inability to monitor 
patient during procedure
•    lack of personnel experienced in airway management or 
interpretation of monitoring equipment
•    lack of resuscitation and airway management equipment
•    children under the age of 2 years should not receive procedural 
sedation unless under the care of an emergency medicine physician 
experienced in paediatric emergency medicine
•    allergy or sensitivity to the prescribed medication (refer to the 
listed contraindications to specific medications as described in the 
latest edition of the South African Medicines Formulary (SAMF)).
6.  Relative contraindications 
Relative contraindications include:
•    facial, dental or airway abnormalities that would preclude tracheal 
intubation
•    patients at high risk of vomiting and aspiration
•    haemodynamically or neurologically unstable patients.
7.  Patient evaluation4,8,9
Obtain a history and perform a physical examination to identify 
medical illnesses, medications, allergies and anatomical features that 
may affect procedural sedation and airway management. The time 
and nature of last oral intake must be documented.
7.1  Medical history and examination6,7,10
The medical history and formal physical examination to be performed 
before administering sedation are to include the following:
•    health and risk assessment history, including allergies, current 
medications, current health problems, previous hospitalisations, 
previous sedation and anaesthetic history
•    vital signs and weight
•    mental health status
•    assessment of airway opening and patency
•    the airway should also be assessed for potential difficulties to bag-
mask ventilate as well as difficult laryngoscopy
•    respiratory status
•    cardiovascular status
•    nil per os (NPO) status
•    developmental status (in paediatric cases).
7.2  Consent8
As part of the consent process, staff members must clearly explain the 
proposed treatment or procedure. The explanation should include 
the following:
•    potential benefits and drawbacks
•    any possible adverse affects of treatment
•    any significant/reasonable alternatives
•    the likelihood of success.
Informed consent for sedation and the procedure is to be obtained 
by documentation on a formal consent form.
7.3  High-risk patients6
Patients at high risk for complications due to procedural sedation 
include individuals with:
•    upper airway obstruction (stridor when awake)
•    sleep apnoea or significant snoring
•    mandibular hypoplasia, craniofacial abnormalities or history of 
difficult airway during anaesthesia or sedation
•    active vomiting, delayed gastric emptying
•    significant gastro-oesophageal reflux, particularly with history of 
aspiration
•    pre-existing significant neurological dysfunction or depressed level 
of consciousness
•    hypovolaemia, cardiac disease or other potential for alteration in 
perfusion
•    pneumonia, reactive airway disease or other disorder of gas 
exchange or pulmonary mechanics
•    history of sedation failure
•    multiple trauma
•    head trauma
•    patients who have ingested a central nervous system depressant 
such as alcohol.
7.4  High-risk techniques6
Sedation techniques with higher risk for complications include:
•    deep sedation, regardless of intended depth or drugs administered
•    non-elective sedation
•    combination drug therapy, particularly opioids and hypnotics
•    medications administered in large doses instead of titrated to effect
•    use of opioids for sedation instead of analgesia.
The planned sedation process will be developed on the basis of 
the assessment information including patient risk documentation, 
assignment of an American Society of Anesthesiologists (ASA) 
physical status score, risk of procedure, and risk of planned sedative 
techniques. Patients with ASA classifications of IV and V should 
NOT be considered for procedural sedation (refer to Appendix 1 for 
ASA classifications).
8. Pre-procedure preparation and 
equipment
The procedure should be performed in a clinical environment where 
monitoring can be done and where access to resuscitative drugs and 
equipment is immediately available. The relevant reversal agents must 
also be available. 
8.1 Equipment4,8
The following equipment should be present:11
•    oxygen and delivery devices (nasal cannula and face mask)
•    suction and suction catheters
•    resuscitation trolley and defibrillator and intubation equipment
•    vital signs monitor (including blood pressure, cardiac monitor and 
saturation)
•    positive-pressure breathing device
•    oral airways of appropriate size
•    advanced cardiac life support medications.
Intravenous (IV) access must be established and maintained, 
except when using an intramuscular technique for the administration 
of ketamine in children.
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9.  Fasting before procedural sedation2 
There is no evidence to show that patients need to be fasted, and 
recent food intake is not a contraindication. The risks and benefits 
of performing procedural sedation on each individual patient need 
to be considered carefully in choosing the timing and target level of 
sedation.
10.  Staff4,7,9,10
Sedation and performance of a procedure require at least two 
appropriately qualified staff (a doctor and a nurse or two doctors): 
one to perform the procedure, and one to be solely responsible for the 
administration of medication, monitoring and documentation.
Observation and monitoring should be done from the start of 
sedation until discharge criteria have been met.
The staff responsible for administering the IV analgesia and 
sedation should be trained in the recognition of complications 
associated with IV sedation. Personnel providing procedural sedation 
and analgesia must have an understanding of the drugs administered, 
ability to monitor the patient’s response to the medications given, 
and the skills necessary to intervene in managing all potential 
complications.
11.  Monitoring and documentation6,7
Assessment of the patient should be done at baseline and every 
5 minutes once the first analgesia/sedation dose has been 
administered. 
The following should be documented:
•    vital signs (blood pressure, heart rate, respiratory rate)
•    electrocardiograph rhythm
•    oxygen saturation
•    airway patency
•    use (or not) of supplemental oxygen 
•    level of consciousness
•    pain
•    medications given, including route, dose and person 
administering.
Capnometry can be considered to provide additional information 
regarding the early identification of hypoventilation, but is not an 
essential requirement of procedural sedation.2,12
Documentation should include the date and time of start of 
sedation, start of procedure and time of conclusion of post-procedure 
care. Adverse events that should be recorded include apnoea or 
airway obstruction requiring intervention, vomiting, aspiration, 
and over-sedation, inadequate sedation, sedation failure or need for 
reversal agents.
12.  Drugs administered4,5,8,13,14
Ketamine, midazolam, fentanyl, propofol and etomidate can all 
safely be administered for procedural sedation and analgesia in 
the emergency centre. Morphine can safely be used as an analgesic 
adjunct (refer to Appendix 2 for drugs and dosages).
Medication doses must be calculated, drawn up and labelled before 
commencement of the procedure. Appropriate antagonists must be 
available and only used if absolutely necessary. Antagonists should 
not be given directly after the procedure in order to ‘reverse’ the 
patient’s sedation and analgesia.
Drugs should be given slowly and in small incremental doses. 
Analgesic agents should generally be administered before sedative 
agents, as over-sedation may result if analgesic medications are given 
after sedation. 
The therapeutic affect should be assessed before the next 
incremental dose is determined and the patient should be observed 
for the following:
•    decrease in oxygen saturation
•    ability to maintain patent airway
•    appropriate response to physical stimulation and/or verbal 
command
•    significant changes in vital signs.
Adjust doses according to patient’s age, level of debilitation, drug 
combinations, tolerance, pulmonary reserve, previous narcotic use 
and length of procedure.
13.  Post-procedure care and discharge 
criteria7,10
The patient should not be left alone at any stage. A trained staff 
member should remain with the patient until discharge. 
13.1 Post-procedure assessments
Post-procedure assessments should be documented:
•    every 15 minutes for 1 hour
•    then every 30 minutes for 1 hour
•    then hourly or until discharge criteria have been met.
•    If the patient receives a reversal agent, they should be observed 
after the procedure for a minimum of 1.5 additional hours.
13.2 Discharge criteria
The following criteria need to be fulfilled before the patient can be 
discharged:
•    Vital signs, level of consciousness, cardiovascular and respiratory 
status have returned to pre-sedation levels.
•    A responsible, designated adult is able to accompany patient and 
transport is available.
•    The patient/caregiver has received appropriate verbal and written 
discharge instructions.
•    Discharge forms are completed and discharge medication has been 
dispensed.
•    Pain is adequately controlled.
•    Nausea/vomiting is controlled.
•    Oxygen saturation is at pre-intervention status.
•    No signs or symptoms that may jeopardise the safety of recovery 
(bleeding, swelling, extreme pain, dizziness, etc.).
•    Follow-up for extended care has been provided.
•    For children: age-appropriate responses are present.
All patients MAY NOT DRIVE home and should not drive for up 
to 24 hours following discharge. The same precaution would apply to 
patients who operate heavy machinery.
Patients with special handicaps, including the blind with or without 
a guide dog, the deaf and mute, and patients with mental illness and/
or mental handicap, may need extra precautions on discharge at the 
discretion of the attending doctor.
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Appendix 1. American Society of Anesthesiology patient 
classification status
ASA I        Normal healthy patient
ASA II        Patient with mild systemic disease; no functional 
limitation, e.g. smoker with well-controlled 
hypertension
ASA III      Patient with severe systemic disease; definite functional 
impairment, e.g. diabetes and angina with relatively 
stable disease, but requiring therapy
ASA IV      Patient with severe systemic disease that is a constant 
threat to life, e.g. patient has dyspnoea on mild exertion 
and chest pain
ASA V        Unstable moribund patient who is not expected to 
survive 24 hours with or without the operation
ASA VI      Brain-dead patient whose organs are removed for 
donation to another
E                Emergency operation of any type – added to any of the 
6 above categories (e.g. ASA II E)
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